Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan(®) and Arulatan(®)) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial

Purpose: To evaluate the therapeutic non-inferiority between two ophthalmic latanoprost 0.005% solutions (Arulatan(®) [ALT] versus the reference drug Xalatan(®) [XLT]) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). Patients and methods: This was a 12-week Phase IV,...

Descripción completa

Detalles Bibliográficos
Autores principales: Brant Fernandes, Rodrigo A, Silva, Luci Meire P, Dias, Diego Torres, Pereira, Rafael Henrique, Belfort, Rubens, Prata, Tiago Santos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499477/
https://www.ncbi.nlm.nih.gov/pubmed/31118553
http://dx.doi.org/10.2147/OPTH.S198229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499477/
https://www.ncbi.nlm.nih.gov/pubmed/31118553
http://dx.doi.org/10.2147/OPTH.S198229

Ejemplares similares